Transfusion Diagnostic Market |

Sources: BCC Research (May 2011) & Immucor Estimates

 
Global transfusion diagnostic market is worth US$30.2 billion; with year-on-year growth of 5% in 2010. The market is stipulated to reach US$45.3 billion, with CAGR of 8.4% (2010-2015). Pre-transfusion diagnostic segment is the biggest constituting 50.6% (2015e: 51%) of total global spending (2010).  The pre-transfusion segment will be the fastest growing worldwide, with CAGR of 8.6% in next 5 years (2010-2015). Post transfusion diagnostic segment will reach US$22.2 billion by 2015.
United States is the biggest marketspace worldwide contributing 46% (2015e: 43%) of total transfusion diagnostic spending (2010). Asia will be the fastest emerging markets globally, accounting for 24% (2010: 21%) of total in 2015. Japan is the biggest market across Asia. In 2010, transfusion grouping & typing based diagnostic reagent and equipment segment is worth US$15.9 billion (2015: US$26.6 billion). Transfusion processing centric diagnostic segment is smallest accounting for remaining 47% of total global marketspace.
Global transfusion diagnostic market is slightly fragmented with three largest manufacturers (Immucor, Johnson & Johnson/Ortho-Clinical Diagnostics and Beckman/Olympus) controlling approximately 10-12% of total market share in 2010. Johnson & Johnson’s wholly owned subsidiary Ortho-Clinical Diagnostic is the largest transfusion diagnostic equipment and solution provider with estimated market share of 7-8% (2010). Beckman/Olympus is the second leading with estimated value share of 3% of global transfusion diagnostic marketspace.
The market has witnessed low merger & acquisition based consolidation worldwide in past 2-3 years (2009-2011). The merger & acquisition has slightly improved with high value based transactions in second half of 2011 (Immucor and Beckman Coulter). In June 2011, IVD Acquisition Corporation (wholly owned subsidiary of TPG Capital) acquired Immucor for US$2 billion.  On the other hand, Danaher Corporation purchased 100% equity in Beckman Coulter for US$6.8 billion (February 2011).  Majority of merger & acquisition across global transfusion diagnostic segment has been to improve regional and local market expansion (i.e. GTI Diagnostic acquisition by Gen-Probe; Bio-Rad purchase of BioTest).
In the next 5-10 years, stringent regulation related to safe blood transfusion, aging population in advanced economies such as United States, United Kingdom, Japan etc along with increased cancer population in Denmark, Ireland, Australia and New Zealand will improve diagnostic demand on long-term basis. Majority of dominant manufacturers (Abbott, Immucor, Johnson & Johnson etc) will vertically integrating transfusion diagnostic product portfolio to improve regional and international brand penetration and customer segmentation (2011-2015). Although United States will be the dominant marketspace (4.5 million population requiring annual transfusion diagnostic) the growing population and healthcare infrastructure across Asia will improve long-term competitive advantage.
 
Sources: BCC Research (May 2011), Immucor Annual Report (2011), www.genomeweb.com, World Cancer Research Fund (2011), www.redcrossblood.org, EDMA Annual Report (2010), World Health Organisation (2011) and www.sysmex.co.jp

Nos études de marché en France et en Europe

Télécharger un exemple

Étude sur Transfusion Diagnostic Market | France

Synthèse du marché en France · Fiches des entreprises · Mise à jour 48h ouvrées

89 €

ACHETER

Étude sur Transfusion Diagnostic Market | Allemagne

Synthèse du marché en Allemagne · Fiches des entreprises · Livraison 5 jours ouvrés

89 €

ACHETER

Étude sur Transfusion Diagnostic Market | UK

Synthèse du marché au UK · Fiches des entreprises · Livraison 5 jours ouvrés

89 €

ACHETER

Étude sur Transfusion Diagnostic Market | Italie

Synthèse du marché en Italie · Fiches des entreprises · Livraison  5 jours ouvrés

89 €

ACHETER

Étude sur Transfusion Diagnostic Market | Espagne

Synthèse du marché en Espagne · Fiches des entreprises · Livraison 5 jours ouvrés

89 €

ACHETER

Étude sur Transfusion Diagnostic Market | Belgique

Synthèse du marché en Belgique · Fiches des entreprises · Livraison 5 jours ouvrés

89 €

ACHETER

Étude sur Transfusion Diagnostic Market | Portugal

Synthèse du marché au Portugal · Fiches des entreprises · Livraison 5 jours ouvrés

89 €

ACHETER

Nos études de marché dans le monde

Télécharger un exemple

Immucor/TPG Capital

  • Pays : États-Unis
  • Chiffre d’affaires : Group Revenues (2011): US$0.33 billion
  • Position : Pre-transfusion diagnostics provider

One of the leading transfusion diagnostics provider worldwide, with strong market penetration across United States. The company offers horizontally integrated reagents cell & serum detecting automated systems with hospital and donor centres as core customer base. It is wholly owned subsidiary of TPG Capital. The company was incepted in 1982.

Ortho-Clinical Diagnostics/J&J

  • Pays : États-Unis
  • Chiffre d’affaires : Group Revenues (2010): US$2 billion
  • Position : Pre & Post transfusion diagnostics provider

Largest transfusion diagnostic equipment and solution provider globally incorporated in 1944. The company is wholly owned operations of Johnson & Johnson diagnostic business activity acquired in 1994. It has three manufacturing facilities in United States and United Kingdom.

Olympus/Beckman

  • Pays : États-Unis
  • Chiffre d’affaires : Group Revenues (2010): US$0.5 billion
  • Position : Pre transfusion diagnostics provider

One of the biggest transfusion diagnostics plaform and equipment manufacturer worldwide, with parent enterprise (Olympus Corporation) established in 1919. The company offers immunoassay and hemostasis solutions with recurring revenue growth of 6.4% in 2010. It is wholly owned operations of Beckman Coulters.

GTI Diagnostic/Gen-Probe

  • Pays : États-Unis
  • Chiffre d’affaires : Group Revenues (2010): US$13 million
  • Position : Pre transfusion diagnostics provider

Wholly owned subsidiary of Gen-Probe focussing on transplantation, blood bank and specialty coagulation consumer base. It was incorporated as operations of BloodCenter of Wisconsin Research Foundation in May 1985.

Bio-Rad

  • Pays : États-Unis
  • Chiffre d’affaires : Group Revenues (2011): US$2.1 billion
  • Position : Pre & Post transfusion diagnostics provider

Highly vertically diversified transfusion diagnostics solution provider worldwide with strong market presence in United States and Europe. It provides blood transfusion testing, transplantation and infectious diseases product portfolio to 85,000 customer base (2011). The company is publicly listed on New York Stock Exchange.

Abbott

  • Pays : États-Unis
  • Chiffre d’affaires : Group Revenues (2010): US$31 billion
  • Position : Pre transfusion diagnostics provider

One of the early movers into transfusion diagnostics equipment and reagent manufacturing across United States, New Zealand, Australia and Europe. The company primarily offers transfusion diagnostic product portfolio focussing on infectious diseases, cancer and diabetes. It is wholly owned operations of Abbott Laboratories incorporated in 1888.

BioMerieux

  • Pays : France
  • Chiffre d’affaires : Group Revenues (2010): US$1.8 billion
  • Position : Pre & Post transfusion diagnostics provider

One of the largest transfusion diagnostics equipment and solution provider across Europe with strong presence in cancer and cardiovascular and infectious disease marketspace. It is publicly listed on Euronext Paris, with market capitalisation of US$4.1 billion (September 2011). The company was established in 1963.

Fujirebio

  • Pays : États-Unis
  • Chiffre d’affaires : Group Revenues (2010): US$52 million
  • Position : Pre & Post transfusion diagnostics provider

One of the fastest emerging transfusion diagnostics solution provider in United States, incepted in 1979. The company provides oncology centric transfusion diagnostics equipment and reagents. It is wholly owned operations of Miraca Holdings Inc.

Roche

  • Pays : Suisse
  • Chiffre d’affaires : Group Revenues (2010): US$45 billion
  • Position : Pre & Post transfusion diagnostics provider

One of the highly horizontally integrated transfusion diagnostics equipment and reagent distributor worldwide established in 1896. The company primarily focusses on reagent for HIV, the hepatitis C virus and the hepatitis B virus. The parent corporation is publicly traded on Zürich Stock Exchange with market capitalisation of US$146.5 billion (September 2011).

Haemonetics

  • Pays : États-Unis
  • Chiffre d’affaires : Group Revenues (2011): US$0.6 billion
  • Position : Pre & Post transfusion diagnostics provider

One of the fastest growing transfusion diagnostics reagent and solution manufacturer and distributor worldwide, with domestic market accounting for 47% of group revenues (2011). Japan is the second core market for Haemonetics contributing 16% of total. The company was incepted in 1985.

Alere

  • Pays : États-Unis
  • Chiffre d’affaires : Group Revenues (2011): US$2.1 billion
  • Position : Pre transfusion diagnostics provider

Vertically diversified health management system provider with niche penetration in transfusion diagnostics equipment marketspace globally. The company is publicly listed on New York Stock Exchange, with market capitalisation of US$2 billion (2011). It was incorporated in 1992. Europe accounted for 17% of group revenues.

OraSure Technologies

  • Pays : États-Unis
  • Chiffre d’affaires : Group Revenues (2011): US$75 million
  • Position : Pre transfusion diagnostics provider

One of the horizontally integrated healthcare diagnostics equipment and solution manufacturer, with domestic market constributing 85% of group revenues in 2010. It is publicly traded on NASDAQ stock exchange, with market capitalisation of US$341 million (2011). Oral fluid diagnostics is the core business segment. OraSure Technologies was established in 2000.

Novartis Diagnostics

  • Pays : Suisse
  • Chiffre d’affaires : Group Revenues (2010): US$51.5 billion
  • Position : Pre & Post transfusion diagnostics provider

One of the oldest transfusion diagnostics provider globally, offering medicines, preventive vaccines, diagnostic tools, generic pharmaceuticals and consumer health products. The parent corporation is publicly traded on New York Stock Exchange, with market capitalisation of US$125 billion. United States is the flagship market accounting for 33% of group revenues (2010).

Tecan

  • Pays : Suisse
  • Chiffre d’affaires : Group Revenues (2010): US$0.37 billion
  • Position : Pre transfusion diagnostics provider

Niche transfusion diagnostics manufacturer, offering screening equipment and solution portfolio across United States and Europe. Liquid handling & robotics is the core business activity accounting for 70% (2007: 63%) of group revenues (2010). The domestic market contributed 2.1% of total.

Orchid Cellmark/LabCorp

  • Pays : États-Unis
  • Chiffre d’affaires : Group Revenues (2010): US$63 million
  • Position : Pre transfusion diagnostics provider

Wholly owned operations of Laboratory Corporation of America Holdings acquired for US$85 million in April 2011. The parent corporation registered net revenues of US$5 billion in 2010. It offers DNA testing and screening centric transfusion diagnostics equipment and solutions.

À propos de nous